CRF Health’s TrialMax eCOA Solution Selected for Landmark Pain Outcomes Study

Article

Applied Clinical Trials

CRF Health announced that its TrialMax Touch and TrialMax Slate solutions have been selected by a Global Category Japanese Pharmaceutical company for a pain outcomes study. The Phase III trial will involve 800 screened and 320 randomized subjects across 40 sites in the US.

Read the full release here.

Recent Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.